Post‑Operative Management After Transcarotid Arterial Revascularization (TCAR)
Blood‑Pressure Management
- Immediate and long‑term antihypertensive therapy is required after TCAR (Class I). The American College of Cardiology and the European Society of Cardiology recommend routine use of antihypertensive agents to maintain hemodynamic stability in the peri‑operative period. 1, 2, 3
- Post‑operative hypertension is a major risk factor for stroke, transient ischemic attack, wound bleeding, and intracranial hemorrhage, necessitating aggressive pharmacologic control. Evidence from the European Society of Cardiology highlights the association between uncontrolled systolic pressure and adverse cerebrovascular events. 3
- Both hypertension and hypotension must be treated promptly because fluctuations in either direction are common and can lead to neurologic injury. The European Society of Cardiology emphasizes rapid correction of blood‑pressure excursions to protect cerebral perfusion. 3
Antiplatelet Therapy
- Dual antiplatelet therapy (aspirin 81–325 mg daily + clopidogrel 75 mg daily) is mandatory for at least 30 days after TCAR (Class I). The American College of Cardiology and the European Society of Cardiology endorse this regimen to prevent early stent thrombosis. 1, 2, 3
- If clopidogrel is intolerant, ticlopidine 250 mg twice daily may be substituted. Supported by recommendations from the American College of Cardiology and the Journal of Neurointerventional Surgery. 1, 2
- Ticagrelor should be avoided in TCAR DAPT regimens because it is associated with a higher bleeding risk compared with clopidogrel. The European Society of Cardiology advises against its routine use in this setting. 3
- After the initial 30‑day DAPT period, patients should transition to lifelong single‑antiplatelet therapy (either aspirin 75–325 mg daily or clopidogrel 75 mg daily). This recommendation follows American College of Cardiology guidance. 2
Neurological Assessment
- A formal neurological examination must be documented within 24 hours before and after the TCAR procedure (Class I). Both the American College of Cardiology and the Journal of Neurointerventional Surgery require this to detect early neurologic complications. 1, 2
Lipid‑Lowering Therapy
- Intensive lipid‑lowering therapy should be initiated or continued, aiming for >50 % LDL‑C reduction and an LDL‑C target <1.4 mmol/L (≈55 mg/dL). The European Society of Cardiology recommends these goals to reduce long‑term atherosclerotic risk after carotid revascularization. 3
Imaging and Clinical Surveillance
- Duplex ultrasound should be performed within the first month post‑procedure to establish a baseline and assess arterial patency (Class I). This recommendation is endorsed by the European Society of Cardiology. 3
- Follow‑up imaging (e.g., CTA, MRA, or duplex) at 6 months and then annually is advised to monitor for restenosis and the development of new or contralateral lesions. The American College of Cardiology and European Society of Cardiology provide concordant guidance. 1, 2, 3
- Annual clinical follow‑up is recommended to evaluate cardiovascular risk factors, medication adherence, and any neurologic symptoms. This practice is supported by the European Society of Cardiology. 3
Post-Operative Care for TransCarotid Artery Revascularization (TCAR)
Immediate Post-Operative Management
- Patients undergoing TCAR should receive dual antiplatelet therapy (aspirin 81-325 mg plus clopidogrel 75 mg daily) for at least 30 days post-procedure, with close hemodynamic and neurological monitoring in a step-down unit rather than ICU for most patients 4, 5, 6
- Formal neurological examination must be documented within 24 hours after the procedure 7, 8
- Blood pressure fluctuations (both hypertension and hypotension) are common and must be treated promptly 4, 5
- Post-operative hypertension increases risk of stroke, TIAs, wound bleeding, and intracranial hemorrhage and requires aggressive pharmacological control 4, 5
Antiplatelet Therapy
- Aspirin 81-325 mg daily PLUS clopidogrel 75 mg daily for a minimum of 30 days post-procedure (Class I recommendation) 4, 5, 6, 7, 8
- Avoid ticagrelor in DAPT regimens following TCAR due to elevated bleeding risk compared to clopidogrel 4, 5
Blood Pressure Management
- Antihypertensive medications must be administered to control blood pressure both immediately post-procedure and long-term (Class I recommendation) 7, 8
- Target blood pressure control to prevent both hypertensive complications and hypotension-related cerebral hypoperfusion 4, 5
Additional Medical Management
- Initiate or continue intensive lipid-lowering therapy targeting >50% LDL-C reduction and LDL-C <1.4 mmol/L (55 mg/dL) 4, 5
- Statin therapy should be administered to all patients regardless of baseline lipid levels 9
Surveillance Imaging
- Duplex ultrasound surveillance within the first month post-procedure to establish baseline and assess patency 4, 5, 6, 9
- Follow-up imaging at 6 months to exclude development of new or contralateral lesions 7, 8, 9
- Annual surveillance thereafter to monitor for restenosis 4, 5, 6, 7, 8, 9